Neoadjuvant and Adjuvant Therapies Are Shifting Surgery Timing

Pfizer (PFE) and Astellas Pharma (4503)'s Padcev (enfortumab vedotin, Nectin-4-targeting ADC) and Merck & Co. (MRK)'s Keytruda (pembrolizumab, PD-1 inhibitor) reduced the risk of progression and death by 55% and the risk of death by 53% in the Phase 3 EV-302 trial. The median overall survival at 3.5 years of follow-up was 33.6 months, significantly outperforming chemotherapy's 15.9 months. This combination expanded FDA approval in November 2025 for cisplatin-ineligible patients and on July 10, 2026, for cisplatin-eligible and -ineligible muscle-invasive bladder cancer in the perioperative setting. The validated ADC and immunotherapy combination is now entering curative-stage treatment, directly replacing the gemcitabine-cisplatin-based standard of care in the metastatic market.

Immunotherapy Competition Expands Across All Stages

AstraZeneca (AZN)'s Imfinzi (durvalumab, PD-L1 inhibitor) recorded a 2-year disease-free survival rate of 67.8% and overall survival rate of 82.2% in the Phase 3 NIAGARA trial when combined with gemcitabine-cisplatin pre-surgery and administered post-surgery, earning FDA approval in March 2025. On May 28, 2026, it secured BCG combination approval for high-risk non-muscle-invasive bladder cancer patients without prior BCG treatment based on a 32% risk reduction in the Phase 3 POTOMAC trial. As a result, Imfinzi now competes with Padcev and Keytruda in cisplatin-eligible muscle-invasive patients and reinforces the long-standing standard of intravesical BCG in early non-muscle-invasive disease. Clinical competition is shifting from simple response rates to bladder preservation, recurrence suppression, and treatment intensity optimization.

ctDNA Lowers Barriers for Adjuvant Therapy Patient Selection

Roche (RHHBY)-affiliated Genentech's Tecentriq (atezolizumab, PD-L1 inhibitor) extended disease-free survival from 4.8 to 9.9 months and overall survival from 21.1 to 32.8 months in ctDNA-positive patients with molecular residual disease after surgery in the Phase 3 IMvigor011 trial. On May 15, 2026, the FDA approved Tecentriq adjuvant therapy alongside Natera (NTRA)'s personalized next-generation sequencing companion diagnostic Signatera CDx. The disease-free survival rate in the continuously ctDNA-negative group was 95% at one year and 88% at two years. This is the first approved model to detect recurrence risk earlier than imaging and direct drug prescriptions to high-risk patients, linking companion diagnostic revenue with oncology prescriptions.

Bladder Preservation and Precision Medicine Are the Next Market Pillars

For BCG-unresponsive non-muscle-invasive disease, Ferring Pharmaceuticals' Adstiladrin (nadofaragene firadenovec, IFNα2b gene therapy), ImmunityBio (IBRX)'s Anktiva (nogapendekin alfa inbakicept, IL-15 receptor modulator) with BCG, and Johnson & Johnson (JNJ)'s Inlyta (gemcitabine, DNA synthesis-inhibiting antimetabolite) are FDA-approved bladder preservation alternatives. For progressive FGFR3-mutated disease, Erdafitinib (FGFR1-4 inhibitor) is commercially available, while Tyra Biosciences (TYRA)'s Davolgitinib (TYRA-300, selective FGFR3 inhibitor) has entered Phase 2 for intermediate-risk non-muscle-invasive disease. HER2-targeting ADC Dacetuzumab Vedotin and Nectin-4-targeting Bicycle conjugate Zelidnexide Pevodotin are challenging the existing Padcev paradigm in Phase 3 and Phase 2/3 trials, respectively. The global bladder cancer treatment market is projected to grow from USD 6.41 billion in 2026 to USD 9.93 billion in 2032, with ADCs, immunotherapies, and MRD diagnostics as key growth drivers.